The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice

The role of Mrp2, Bcrp, and P-glycoprotein in the biliary excretion of acetaminophen sulfate (AS) and glucuronide (AG), 4-methylumbelliferyl sulfate (4MUS) and glucuronide (4MUG), and harmol sulfate (HS) and glucuronide (HG) was studied in Abcc2(-/-), Abcg2(-/-), and Abcb1a(-/-)/Abcb1b(-/-) mouse livers perfused with the respective parent compounds using a cassette dosing approach. Biliary clearance of the sulfate conjugates was significantly decreased in Bcrp-deficient mouse livers, resulting in negligible biliary excretion of AS, 4MUS, and HS. It is noteworthy that the most profound decrease in the biliary clearance of the glucuronide conjugates was observed in Bcrp-deficient mouse livers, although the biliary clearance of 4MUG was also ∼35% lower in Mrp2-deficient mouse livers. As expected, biliary excretion of conjugates was not impaired in P-glycoprotein-deficient livers. An appreciable increase in perfusate recovery due to a shift in the directionality of metabolite excretion, from bile to perfusate, was noted in knockout mice only for conjugates whose biliary clearance constituted an appreciable (≥37%) fraction of total hepatic excretory clearance (i.e., 4MUS, HG, and HS). Biliary clearance of AG, AS, and 4MUG constituted a small fraction of total hepatic excretory clearance, so an appreciable increase in perfusate recovery of these metabolites was not observed in knockout mice despite markedly decreased biliary excretion. Unlike in rats, where sulfate and glucuronide conjugates were excreted into bile predominantly by Mrp2, mouse Bcrp mediated the biliary excretion of sulfate metabolites and also played a major role in the biliary excretion of the glucuronide metabolites, with some minor contribution from mouse Mrp2.

[1]  Y. Sugiyama,et al.  Reduced Gastrointestinal Toxicity Following Inhibition of the Biliary Excretion of Irinotecan and Its Metabolites by Probenecid in Rats , 2002, Pharmaceutical Research.

[2]  Kim L R Brouwer,et al.  Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Yuichi Sugiyama,et al.  Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen , 2005, Molecular Pharmacology.

[4]  Y. Sugiyama,et al.  Species differences in the transport activity for organic anions across the bile canalicular membrane. , 1999, The Journal of pharmacology and experimental therapeutics.

[5]  D. Meijer,et al.  Mrp2 is essential for estradiol‐17β(β‐D ‐glucuronide)–induced cholestasis in rats , 2000 .

[6]  Y. Sugiyama,et al.  Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[7]  J. Fritschy,et al.  Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood–brain barrier , 2006, Neuroscience.

[8]  Y. Sugiyama,et al.  Kinetic Analysis of Hepatobiliary Transport for Conjugated Metabolites in the Perfused Liver of Mutant Rats (EHBR) with Hereditary Conjugated Hyperbilirubinemia , 1995, Pharmaceutical Research.

[9]  H. Kusuhara,et al.  Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[11]  Peijin Zhang,et al.  Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. , 2003, Molecular pharmacology.

[12]  K. Brouwer,et al.  MULTIPLE MECHANISMS ARE INVOLVED IN THE BILIARY EXCRETION OF ACETAMINOPHEN SULFATE IN THE RAT: ROLE OF MRP2 AND BCRP1 , 2005, Drug Metabolism and Disposition.

[13]  T. Maurer,et al.  RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE , 2005, Drug Metabolism and Disposition.

[14]  Thomas J. Raub,et al.  ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2′,7′-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE , 2006, Drug Metabolism and Disposition.

[15]  L. Huang,et al.  Adenosine triphosphate-dependent transport of estradiol-17beta(beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells. , 1998, Hepatology.

[16]  T. Horie,et al.  FUNCTIONAL ANALYSIS OF DOG MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2) IN COMPARISON WITH RAT MRP2 , 2005, Drug Metabolism and Disposition.

[17]  P. Borst,et al.  Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene , 2005, Hepatology.

[18]  K. Brouwer,et al.  Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[19]  Kim L. R. Brouwer,et al.  Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[20]  L. Puddington,et al.  Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. , 1993, Biochemical pharmacology.

[21]  C. Funk,et al.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.

[22]  Liyue Huang,et al.  Adenosine triphosphate–dependent transport of estradiol‐17β(β‐d‐glucuronide) in membrane vesicles by MDR1 expressed in insect cells , 1998 .

[23]  Ronald T. Borchardt,et al.  Pharmaceutical profiling in drug discovery for lead selection , 2004 .

[24]  X. Chu,et al.  Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2) , 2006, Journal of Pharmacology and Experimental Therapeutics.

[25]  A. Dahan,et al.  Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.